Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Free Cash Flow (2016 - 2025)

ImmunityBio (IBRX) has disclosed Free Cash Flow for 12 consecutive years, with -$71.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 17.14% to -$71.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$306.3 million through Dec 2025, up 21.86% year-over-year, with the annual reading at -$306.3 million for FY2025, 21.86% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$71.2 million at ImmunityBio, down from -$68.1 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$63.2 million in Q3 2021, with the low at -$123.2 million in Q4 2023.
  • Average Free Cash Flow over 5 years is -$91.0 million, with a median of -$94.4 million recorded in 2023.
  • The sharpest move saw Free Cash Flow plummeted 114.63% in 2021, then soared 30.3% in 2024.
  • Over 5 years, Free Cash Flow stood at -$99.6 million in 2021, then decreased by 10.08% to -$109.7 million in 2022, then dropped by 12.37% to -$123.2 million in 2023, then skyrocketed by 30.3% to -$85.9 million in 2024, then increased by 17.14% to -$71.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$71.2 million, -$68.1 million, and -$80.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.